{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:36:51Z","timestamp":1793137011138,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016619","name":"MyoKardia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jchf.2022.03.002","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T15:52:45Z","timestamp":1651679565000},"page":"531-539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic\u00a0Cardiomyopathy"],"prefix":"10.1016","volume":"10","author":[{"given":"Michael","family":"Nassif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer T.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Dolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Reaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithvi","family":"Addepalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veleka D.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Sehnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensey","family":"Gosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Spertus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2022.03.002_bib1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2022.03.002_bib2","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2022.03.002_bib3","series-title":"Treatment for Heart\u00a0Failure: Endpoints for Drug Development Guidance for Industry","year":"2019"},{"key":"10.1016\/j.jchf.2022.03.002_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853","article-title":"Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy","volume":"13","author":"Ho","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2022.03.002_bib5","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2022.03.002_bib6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1161\/CIRCHEARTFAILURE.113.000359","article-title":"Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction","volume":"6","author":"Joseph","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2022.03.002_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/CIRCHEARTFAILURE.112.970053","article-title":"Use of the Kansas City Cardiomyopathy Questionnaire for monitoring health status in patients with aortic stenosis","volume":"6","author":"Arnold","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2022.03.002_bib8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s41687-020-00269-8","article-title":"Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life","volume":"4","author":"Zaiser","year":"2020","journal-title":"J\u00a0Patient Rep Outcomes"},{"issue":"10293","key":"10.1016\/j.jchf.2022.03.002_bib9","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2022.03.002_bib11","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/jamacardio.2017.3983","article-title":"Association of serial Kansas City Cardiomyopathy Questionnaire assessments with death and hospitalization in patients with heart failure with preserved and reduced ejection fraction: a secondary analysis of 2 randomized clinical trials","volume":"2","author":"Pokharel","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2022.03.002_bib12","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1161\/CIRCULATIONAHA.108.820472","article-title":"Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS)","volume":"119","author":"Chan","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2022.03.002_bib13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ahj.2004.12.010","article-title":"Monitoring clinical changes in patients with heart failure: a comparison of methods","volume":"150","author":"Spertus","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2022.03.002_bib14","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s11136-016-1267-9","article-title":"Quantifying clinical change: discrepancies between patients' and providers' perspectives","volume":"25","author":"Dreyer","year":"2016","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jchf.2022.03.002_bib15","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review","volume":"76","author":"Spertus","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2022.03.002_bib16","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/hrt.2006.089656","article-title":"Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure","volume":"93","author":"Raphael","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2022.03.002_bib17","series-title":"Quality of Life and Pharmacoeconomics in Clinical Trials","first-page":"191","article-title":"The EuroQoL instrument: an index of health-related quality of life","author":"Kind","year":"1996"},{"key":"10.1016\/j.jchf.2022.03.002_bib18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.jchf.2022.03.002_bib19","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.jchf.2022.03.002_bib20","series-title":"Guidance for Industry Patient-Reported Outcomes Measures: Use in Medical Product Development to Support Labeling Claims","year":"2009"},{"issue":"25","key":"10.1016\/j.jchf.2022.03.002_bib21","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1016\/j.jacc.2020.08.044","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2022.03.002_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ahj.2011.09.027","article-title":"Relationships between changes in patient-reported health status and functional capacity in outpatients with heart failure","volume":"163","author":"Flynn","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2022.03.002_bib23","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/ejhf.1788","article-title":"Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity","volume":"22","author":"Reddy","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2022.03.002_bib24","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.jacc.2020.03.002","article-title":"Health Status Changes and Outcomes in Patients With Heart\u00a0Failure and Mitral Regurgitation: COAPT Trial","volume":"75","author":"Arnold","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177922002037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177922002037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:00:59Z","timestamp":1761973259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177922002037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2213177922002037"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2022.03.002","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic\u00a0Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2022.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors and by Myokardia, Inc. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}